New hope for Hard-to-Treat prostate cancer? early trial launches

NCT ID NCT06785636

Recruiting now Disease control Sponsor: Pathos AI, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, so results will guide future research rather than offer immediate treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pocenbrodib (a targeted oral drug) alone or with darolutamide
What this could lead to: If successful, this could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early-phase trial (Phase 1b/2a) focused on safety and dosing, so it is too soon to know if the drug will be effective. Side effects are unknown, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma male reproductive organ cancer metastatic prostate carcinoma neoplasm prostate cancer prostate disorder prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENITAL NEOPLASMS, MALE MALE UROGENITAL DISEASES MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) NEOPLASMS NEOPLASMS BY SITE PROSTATE CANCER PROSTATIC DISEASES PROSTATIC NEOPLASMS UROGENITAL CANCERS UROGENITAL NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cancer and Blood Research Center
RECRUITING

Los Alamitos, California, 90720, United States
Community Health Network
RECRUITING

Indianapolis, Indiana, 46250, United States
Duke University medical center
RECRUITING

Durham, North Carolina, 27710, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
MemorialCare Orange Coast Medical Center
RECRUITING

Fountain Valley, California, 92708, United States
Mount Sinai Medical Center
RECRUITING

Miami, Florida, 33140, United States
NEXT Oncology - Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Ochsner
RECRUITING

Jefferson, Louisiana, 70121, United States
Oncology Consultants, P.A
RECRUITING

Houston, Texas, 77030, United States
Siteman Cancer Center
RECRUITING

St Louis, Missouri, 63108, United States
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States

Contact Email: •••••@•••••
University of Colorado Health
RECRUITING

Aurora, Colorado, 80045, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.